Cancer, EarlyView.
https://ift.tt/2pTz5tG
Δευτέρα 2 Απριλίου 2018
The role of whole‐brain radiation therapy in patients with cerebral metastases
The role of whole‐brain radiation therapy in patients with cerebral metastases
Cancer, EarlyView.
from Cancer via ola Kala on Inoreader https://ift.tt/2pTz5tG
via IFTTT
Κυριακή 1 Απριλίου 2018
No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3)
https://ift.tt/2EctsuP
No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3)
from Cancer via ola Kala on Inoreader https://ift.tt/2EctsuP
via IFTTT
By the Numbers: Novel Drugs Approved by the FDA, 2011-2017 [News in Brief]
In 2017, the FDA approved 12 novel cancer drugs. The agency also approved two chimeric antigen receptor T-cell therapies for blood cancers.
from Cancer via ola Kala on Inoreader https://ift.tt/2GtG0Uv
via IFTTT
The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression [Research Briefs]
We found that the cancerous pancreas harbors a markedly more abundant microbiome compared with normal pancreas in both mice and humans, and select bacteria are differentially increased in the tumorous pancreas compared with gut. Ablation of the microbiome protects against preinvasive and invasive pancreatic ductal adenocarcinoma (PDA), whereas transfer of bacteria from PDA-bearing hosts, but not controls, reverses tumor protection. Bacterial ablation was associated with immunogenic reprogramming of the PDA tumor microenvironment, including a reduction in myeloid-derived suppressor cells and an increase in M1 macrophage differentiation, promoting TH1 differentiation of CD4+ T cells and CD8+ T-cell activation. Bacterial ablation also enabled efficacy for checkpoint-targeted immunotherapy by upregulating PD-1 expression. Mechanistically, the PDA microbiome generated a tolerogenic immune program by differentially activating select Toll-like receptors in monocytic cells. These data suggest that endogenous microbiota promote the crippling immune-suppression characteristic of PDA and that the microbiome has potential as a therapeutic target in the modulation of disease progression.
Significance: We found that a distinct and abundant microbiome drives suppressive monocytic cellular differentiation in pancreatic cancer via selective Toll-like receptor ligation leading to T-cell anergy. Targeting the microbiome protects against oncogenesis, reverses intratumoral immune tolerance, and enables efficacy for checkpoint-based immunotherapy. These data have implications for understanding immune suppression in pancreatic cancer and its reversal in the clinic. Cancer Discov; 8(4); 403–16. ©2018 AACR.
See related commentary by Riquelme et al., p. 386.
This article is highlighted in the In This Issue feature, p. 371
from Cancer via ola Kala on Inoreader https://ift.tt/2GteHpv
via IFTTT
Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling [In the Spotlight]
Summary: Development of pancreatic cancer in spontaneous murine models is associated with enrichment of specific strains of gut and intratumoral bacteria that induce a tolerogenic immunosuppressive microenvironment favoring cancer progression and resistance to immunotherapies. Ablation of the microbiome with antibiotics reshapes the tumor microenvironment, inducing T-cell activation, improving immune surveillance, and increasing sensitivity to immunotherapy in established tumors. Cancer Discov; 8(4); 386–8. ©2018 AACR.
See related article by Pushalkar et al., p. 403.
from Cancer via ola Kala on Inoreader https://ift.tt/2GteEKl
via IFTTT